Aristolochic Acid and Immunotherapy for Urothelial Carcinoma: Directions for unmet Needs
Open Access
- 28 June 2019
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 20 (13) , 3162
Abstract
Urothelial carcinoma of the bladder (UCB) and upper tracts (UTUC) used to share management with similar principles. However, their genetic and epigenetic differences along with different responses to immunotherapy were recently identified, which are reminiscent of their distinct etiologies. Different from the variety of environmental factors relating to UCB, UTUC is best known for its close relationship with exposure to aristolochic acid (AA). AA is believed to cause its carcinogenicity through forming DNA adducts of deoxyadenosine-aristolactam, as well as A:T → T:A transversions in the TP53 tumor suppressor gene. Since recent findings suggested that cancers with higher somatic mutations are associated with better treatment responses upon immune checkpoint blockade, UTUC and AA-related biomarkers reasonably serve as good candidates, as well as a potential prognostic predictor for the flourishing immunotherapy. This review covers the current state of the literature on the clinical response of UTUC and UCB receiving immunotherapy and points out directions for refinement regarding patient selection.Keywords
Funding Information
- Chang Gung Memorial Hospital (CORPG3F0131-3)
This publication has 118 references indexed in Scilit:
- PD-1 is a novel regulator of human B-cell activationInternational Immunology, 2012
- Aristolochic acid-associated urothelial cancer in TaiwanProceedings of the National Academy of Sciences, 2012
- Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acidKidney International, 2012
- Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986Journal of Clinical Oncology, 2012
- Changes in Renal Function Following Nephroureterectomy May Affect the Use of Perioperative ChemotherapyEuropean Urology, 2010
- Population-Based Case-Control Study of Chinese Herbal Products Containing Aristolochic Acid and Urinary Tract Cancer RiskJNCI: Journal of the National Cancer Institute, 2009
- Prescription profile of potentially aristolochic acid containing Chinese herbal products: an analysis of National Health Insurance data in Taiwan between 1997 and 2003Chinese Medicine, 2008
- Aristolochic acid and the etiology of endemic (Balkan) nephropathyProceedings of the National Academy of Sciences, 2007
- CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinomaProceedings of the National Academy of Sciences, 2007
- Prevalence of renal cell carcinoma in patients with ESRD pre-transplantation: A pathologic analysisKidney International, 2002